Navigation Links
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc. today presented preliminary results from a pilot Phase 3 trial of KW-3902, an adenosine A1 receptor antagonist in development for the treatment of patients with acute congestive heart failure (CHF), that indicate a strong trend toward efficacy for the 30 milligram dose. Patients treated with KW-3902 experienced a higher rate of improvement in dyspnea, or shortness of breath, which is a common symptom of CHF, compared to the placebo group, and the results also show that KW-3902 enhances diuresis and mitigates deterioration of renal function that is often experienced by patients undergoing standard treatment. The findings were summarized by Marco Metra, M.D., University of Brescia, Italy and Gadi Cotter, M.D., Duke University School of Medicine, in a Late-Breaking Trials Session at the European Society of Cardiology's Heart Failure Congress 2007 in Hamburg, Germany.

Drs. Metra and Cotter presented preliminary 14-day data from 276 patients out of 304 total patients enrolled in the pilot Phase 3 trial. Hospitalized patients with acute CHF with renal impairment, which was defined as having creatinine clearance of 20 to 80 milliliters per minute, were randomized to placebo or 10, 20 or 30 milligram doses of intravenous KW-3902 administered daily for up to three days. All patients also received intravenous furosemide. In the double-blind trial, 225 patients received KW-3902 and 79 patients received placebo. The trial was not designed to assess the statistical significance of effects.

The primary endpoint for the pilot Phase 3 trial was the proportion of patients in the categories of treatment failure, success or no change. Treatment success was defined as:

    -- improvement in patient-reported dyspnea within 48 hours;

    -- physician determination of patient improvement resulting in conversion

       from intravenous to oral d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
(Date:12/24/2014)... 2014 LifeScienceIndustryResearch.com adds ... Syringe Industry of 178 pages providing 10 ... library. The 2014 Market Research ... a professional and deep research report on ... the report introduces Disposable Syringe basic information ...
(Date:12/24/2014)... 23, 2014  The American Diabetes Association is ... for people with diabetes and that all people ... of statins, in keeping with recent changes to ... American College of Cardiology (ACC) and American Heart ... most recent changes to the Association,s annual revised ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Card, in partnership with The Denver Metro Chamber, announced ... "Preferred Pharmacy" for the program. As part of the ... Drug Card. Coloradans can simply walk into any Walgreens ... through the Colorado Drug Card. Walgreens will also have ...
... a world leading provider of scientific, technical and medical ... today honor eight early career researchers in a range ... Young Researcher Award ceremony. More than 80 university ... attend the award ceremony at the Royal Society in ...
Cached Medicine Technology:Elsevier and the Fulbright Commission Honor UK Research Talent With the UK Scopus Young Researcher Award 2Elsevier and the Fulbright Commission Honor UK Research Talent With the UK Scopus Young Researcher Award 3Elsevier and the Fulbright Commission Honor UK Research Talent With the UK Scopus Young Researcher Award 4
(Date:12/26/2014)... It is said that nothing makes a ... the famous wedding dress supplier, shows its new selection ... gown promotion. , UWDress.com’s navy cocktail gowns are the ... in high fashion styles. Simple dresses in bright neon colors ... they are specially designed for those who want to shine ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... (DaWei Induction Heating Co.) is a comprehensive high-tech business ... of a series of induction heating equipment. Today, the ... induction brazing equipments . , According to a ... refers to the joining of two or more components ... says that there are fundamental differences in the two ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2
... The March for Babies 2008 Official Shoes are Now On ... of,Dimes has teamed up with Famous Footwear(TM) and Dr. Scholl,s(R) ... For the third consecutive year, Famous Footwear and Dr. Scholl,s ... walking shoe styles.,Dr. Scholl,s specially designed one men,s and two ...
... Dialysis Corporation,of America (Nasdaq: DCAI ) announced today ... year financial results on March 13, 2008, after the,close ... conference calls,in conjunction with its quarterly earnings releases, beginning ... following morning, March 14,2008 at 10:00 AM EDT., ...
... JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and ... U.S. Food and Drug Administration (FDA) approved the supplemental ... treatment of manic and mixed episodes associated with Bipolar ... patients (10 to 17 years old). ABILIFY has ...
... study in the Mojave Desert, Calif., has found that soils ... a type of salt, close to the surface. Vulnerable to ... disrupted, this vast source of nitrate could contaminate surface and ... appear in the March issue of Geology . , ...
... of Hematology announce a new partnership to publish the ... available (back to 1997) on Springers online information platform ... and was previously published by Carden Jennings. , Since ... official journal of the Japanese Society of Hematology (JSH), ...
... ATLANTA, Feb. 29 Children,s Healthcare of Atlanta, ... today a,landmark investment in the future of pediatric ... $430 million of the Children,s,endowment toward pediatric research., ... will be,invested in pediatric research," said James E. ...
Cached Medicine News:Health News:Famous Footwear, Dr. Scholl's Step Up to Support March for Babies 2008 2Health News:Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 3Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 4Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 2Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 3Health News:Springer to publish International Journal of Hematology 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 3
Jewelers forceps. Insulated....
Semkin forceps with stops. Insulated....
Gerald bayonet forceps. Insulated....
Cushing forceps. Insulated....
Medicine Products: